Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs
| العنوان: | Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs |
|---|---|
| المؤلفون: | Hiromu Nakajima, Antonio Nino, Inaha Okuda, Timothy Wilson, Lin Yue, Maho Tsuboi, Molly C. Carr, Yutaka Seino |
| المصدر: | Current Medical Research and Opinion. 33:431-438 |
| بيانات النشر: | Informa UK Limited, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Adult, Blood Glucose, Male, medicine.medical_specialty, endocrine system diseases, medicine.drug_class, 030209 endocrinology & metabolism, Type 2 diabetes, 030204 cardiovascular system & hematology, Pharmacology, Hypoglycemia, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Glucagon-Like Peptide 1, Internal medicine, Humans, Hypoglycemic Agents, Medicine, Adverse effect, Aged, Glycemic, Glycated Hemoglobin, business.industry, Biguanide, nutritional and metabolic diseases, Type 2 Diabetes Mellitus, General Medicine, Middle Aged, medicine.disease, Sulfonylurea, Recombinant Proteins, Albiglutide, Diabetes Mellitus, Type 2, Hyperglycemia, Female, business |
| الوصف: | To evaluate the safety and efficacy of once weekly albiglutide added to a single oral antidiabetic drug (OAD) in Japanese patients with inadequately controlled type 2 diabetes mellitus (T2DM).In this phase 3, 1 year study (NCT01777282), patients (N = 374) received albiglutide 30 mg plus a single OAD (sulfonylurea [n = 120], biguanide [n = 67)], glinide [n = 65], thiazolidinedione [n = 61], or α-glucosidase inhibitor [n = 61]). Albiglutide could be increased to 50 mg after Week 4, based on glycemic criteria. Primary endpoints were the incidence of adverse events (AEs) and hypoglycemia; secondary endpoints were changes from baseline at Week 52 in HbAOn-therapy AEs occurred in 78.6% of patients and serious AEs in 2.1%. Common AEs were nasopharyngitis (32.6%), constipation (7.2%), and diabetic retinopathy (5.3%). No serious AEs occurred more than once or were reported in1 patient. Hypoglycemia occurred in 6.4% of patients, mostly in the albiglutide + sulfonylurea (14.2%) and the albiglutide + glinide (6.2%) groups. Albiglutide was uptitrated in 53.2% of patients. Mean baseline HbAWhen combined with a single OAD in Japanese patients with inadequately controlled T2DM, albiglutide led to favorable changes in all glycemic parameters, with minor changes in body weight depending on the background OAD. No new safety concerns were noted. |
| تدمد: | 1473-4877 0300-7995 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fc3f4730907f31b08b7aad2282c5166Test https://doi.org/10.1080/03007995.2016.1261817Test |
| رقم الانضمام: | edsair.doi.dedup.....1fc3f4730907f31b08b7aad2282c5166 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14734877 03007995 |
|---|